

Coverage Criteria:

2020 modafinil (generic Provigil®) or armodafinil (generic Nuvigil®) Prior Authorization Request

Page 1 of 2 (You must complete both pages.)

Fax completed form to: 1-800-408-2386 For urgent requests, please call: 1-800-414-2386

Covered for a diagnosis of shift work disorder (SWD)				
 Covered for the treatment of narcolepsy if the diagnosis of narcolepsy 				
Covered for the treatment of excessive sleepiness associated was a second of the treatment of excessive sleepiness associated was a second of the treatment of excessive sleepiness associated was a second of the treatment of excessive sleepiness associated was a second of the treatment of excessive sleepiness associated was a second of the treatment of excessive sleepiness associated was a second of the treatment of excessive sleepiness associated was a second of the treatment of excessive sleepiness.	vith obstructive sleep	apnea (OSA) if the	diagnosis of obstructive sleep	
apnea (OSA) was confirmed by polysomnography				
Authorization duration: Through end of plan contract year				
Patient information	Prescriber inform	mation		
Patient name	· · · · · · · · · · · · · · · · · · ·		specialty	
Patient insurance ID number	Physician name	Physician name NPI/DEA number		
D. C. d. 11				
Patient address, city, state, ZIP	Physician address, city, state, ZIP			
Patient home telephone number	M.D. office telephone number			
Tationt nome telephone number	W.D. Office telephone number			
Gender Patient date of birth	M.D. office fax nu	M.D. office fax number		
☐ Male ☐ Female				
Diagnosis and medical information				
Medication requested		Frequency		
☐ modafinil tablet: ☐ 100mg ☐ 200mg				
☐ armodafinil tablet: ☐ 50mg ☐ 150mg ☐ 200mg	☐ 250mg			
New prescription OR date therapy initiated	Quantity	Day supply	Expected length of therapy	
Diagnosis (Please check all boxes that apply and include all office		,		
☐ Narcolepsy ☐ Obstructive sleep apnea	(OSA)	☐ Shift work disord	er (SWD)	
Other diagnosis/(ICD 10):				
Please check all boxes that apply:				
1. \square Patient is stable on current drug(s) and/or current quantity,	, and therapy chang	je would likely resu	It in adverse clinical outcomes.	
2. All covered Part D drugs on any tier of the plan's formulary drug and/or would likely have adverse effects for the enrol		ffective for the enro	ollee as the requested formulary	
3. Yes No To improve wakefulness in adult patients widiagnosis of narcolepsy been confirmed by			ith NARCOLEPSY: Has the	
4. Yes No To improve wakefulness in adult patients we APNEA (OSA): Has the diagnosis of OSA be			ith OBSTRUCTIVE SLEEP	

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.



Page 2 of 2

Р	lease ch	eck all bo	exes that apply (continued):					
5. Please complete this section only if your patient does not meet the standard requirements listed in question 3 and 4 above: Please explain why your patient should be considered for an exception although they don't meet the plan's suggested PA criteria. Statement should include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)								
6.	. ☐ Yes ☐ No Modafinil 100mg and ALL strengths of armodafinil have a quantity limit of 30 tablets per 30 days. Modafinil 200mg has a quantity limit of 60 tablets per 30 days.							
				gher dosage (quantity limit exception				
			► If yes, indicate quantity red	quested: per 30 days	OR quantity	per day		
	☐ The number of doses available under the dose restriction for the prescription drug has been ineffective in the treatment of the enrollee's disease or medical condition.							
	☐ The number of doses available under the dose restriction for the prescription drug, based on both sound clinical evidence and medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee, and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug's effectiveness or patient compliance.							
7.	☐ Pleas	se list all	medications the patient has	tried specific to the diagnosis and	specify below.			
	CURRE	NT/PAST	MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC	OUTCOME		
	OOKKE	111/1/401	MEDICATIONS SOLD	DATES OF TREATMENT	THERAI EOTIO	COLOGINE		
a	☐ Othe	r sunnor	ting information			<u> </u>		
٥.			•	er supporting statements Additionally	requests that ar	e subject to prior authorization (or		
	*NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.							
						<u> </u>		
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or								
				person who knowingly makes or cause				
material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have								
obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and								
Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.								
F	Prescribe	er signatı	ure			Date		

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.